LBLiudmila A. Bessonova

Liudmila A. Bessonova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Liudmila A. Bessonova has a total of 135 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • STANKIEWICZ–ISIDOR SYNDROME CAUSED BY A MICRODELETION OF THE LONG ARM OF CHROMOSOME 17: A CASE REPORT AND LITERATURE REVIEW

    by A.S. Iakovleva, Zh.G. Markova, L.A. Bessonova, N.V. Shilova

    Stankiewicz–Isidor syndrome (STISS; OMIM #617516) is a rare autosomal dominant disorder caused by haploinsufficiency of the PSMD12 gene. Most reported cases are associated with point variants in the PSMD12 gene, whereas microdeletions involving this locus are much rarer. We present a clinical case of an 8-month-old girl with psychomotor developmental delay, muscular hypotonia, craniofacial anomalies, and congenital heart defect. Standard karyotyping revealed no pathology. Whole-exome sequencing suggested a microdeletion of chromosome 17. Chromosomal microarray analysis (CMA) revealed a heterozygous 3.42 Mb microdeletion at 17q23.3q24.2, including the PSMD12 gene and a number of neighboring genes. The patient's phenotype was largely consistent with literature data; however, the presence of a pilonidal sinus has not been previously described in patients with STISS. Conclusion: this case report expands the current understanding of the phenotypic spectrum of Stankiewicz–Isidor syndrome and highlights the high diagnostic value of CMA in patients with syndromic pathology and normal karyotype.

  • Open Access

    Independent coexistence of diseases in neurogenetics: case reports and literature review

    by Galina E. Rudenskaya, Руденская Галина Евгеньевна, A. S. Kuchina, Кучина Анна С., E. A. Melnik, Мельник Евгения А., I. V. Sharkova, Шаркова Инна В., T. S. Nagornova, Нагорнова Татьяна С., et al.

    Combined hereditary pathology (“double trouble”) in a patient and/or family, previously considered a rarity, is being identified increasingly often due to the development of modern genetic diagnostic methods. We describe 13 patients from 12 families with two hereditary diseases of the nervous system, verified by DNA analysis. The spectrum of diseases includes 23 nosological forms, including a number of rare ones. The cases differ in their diagnostic pathways (clinical diagnoses of two diseases and their laboratory confirmation; an unusual clinical presentation of the first disease followed by a targeted search for the second; unexpected findings during molecular genetic testing) and DNA analysis methods (massive parallel sequencing: panel, whole-exome and whole-genome sequencing; targeted methods: sequencing of individual genes and testing for common pathogenic variants; molecular cytogenetic methods). Among the identified gene variants, 8 have not been previously described. The cases are discussed in comparison with literature data on neurogenetic “double troubles”.

  • Open Access

    Experience in Molecular Genetic Diagnostics of Birt–Hogg–Dubé Syndrome: Characteristics of Identified Mutations and Evolution of the Methodological Approach

    by Irina G. Sermyagina, Dmitry S. Mikhaylenko, Natalya B. Kuryakova, Viktoria V. Musatova, Olga A. Solovova, Anait E. Voskanyan, Ludmila A. Bessonova, Yulia L. Melyanovskaya, Elena I. Kondratyeva, Alexander V. Polyakov, et al.

    Birt–Hogg–Dubé syndrome (BHDS) is a hereditary cancer syndrome caused by pathogenic variants in the FLCN gene. BHDS is characterized by clinical heterogeneity and similarities with other non-hereditary diseases, which can complicate diagnosis. The aim of our study was to analyze FLCN variants in Russian patients and select the optimal diagnostic approach. We studied 121 unrelated patients suspected for BHDS and 29 of their relatives. Germline variants were analyzed using Sanger sequencing and Multiplex Ligation-dependent Probe Amplification (MLPA). Variant annotation was performed according to the ACMG and AMP recommendations. Pathogenic and likely pathogenic (P/LP) FLCN variants were identified in 20.7% of patients, including six new variants. The distribution of FLCN variants in our cohort was consistent with data obtained from other authors. The mean age of patients with P/LP variants was higher than of those without: 46.91 versus 33.8 years (p < 0.05), suggesting the necessity to apply diagnostic criteria in young patients more carefully. The most common clinical manifestation of BHDS was pulmonary cysts/pneumothorax, while the most informative were alterations involving at least two of three organ systems, which was present in all patients with the P/LP variants, but only in 54% without them (p = 0.001). BHDS diagnostics involves sequencing exons 4–14 of the FLCN gene in patients with proposed clinical criteria. If the result is negative, extensive FLCN deletions are excluded using MLPA, and, in the absence of CNV, WGS is performed.

  • Open Access

    A rare case of uniparental disomy 9 concomitant with low-level mosaicism

    by A. S. Iakovleva, Zh. G. Markova, L. A. Bessonova, N. V. Shilova

    Uniparental disomy of chromosome 9, in combination with low-level mosaicism for chromosome 9, represents a rare chromosomal disorder. One of the mechanisms underlying the formation of uniparental disomy is the trisomy rescue, which concurrently results in low-level mosaicism. The diagnosis of mosaic aneuploidies poses significant challenges due to the limited sensitivity and resolution of conventional cytogenetic methods, which often fail to detect low-level mosaicism. Additionally, the variable distribution of cell lines within the patient’s tissues, as well as the heterogeneity of samples derived from the same tissue, complicates the precise determination of the impact of mosaic trisomy on the phenotypic expression. Phenotypic manifestations associated with mosaic trisomy 9 are characterized by considerable variability. During the prenatal period, intrauterine growth restriction is frequently observed in cases of this chromosomal abnormality, although this finding is not pathognomonic for the condition. In liveborn infants with trisomy 9 mosaicism, characteristic phenotypic features may include craniofacial anomalies (such as micrognathia and ear malformations), scoliosis, low-set ears, feeding and respiratory difficulties, hip dysplasia, seizures, and developmental delays. To establish a diagnosis in a patient presenting with multiple dysembryogenic stigmata and psychomotor retardation, a comprehensive molecular cytogenetic analysis was conducted. This included high-resolution chromosomal microarray analysis (CMA) and fluorescence in situ hybridization (FISH) using targeted DNA probes. CMA identified regions of loss of heterozygosity (LOH) on chromosome 9, indicative of uniparental disomy, and suggested the presence of low-level mosaicism for trisomy 9. Subsequent FISH analysis of cultured lymphocytes, employing DNA probes specific to various regions of chromosome 9, confirmed the low-level mosaicism for trisomy 9. The results of our study are consistent with the idea that mosaicism for chromosome 9, particularly when combined with uniparental disomy, constitutes a complex genetic anomaly that can lead to a spectrum of phenotypic manifestations, including developmental delay, growth abnormalities, and behavioral anomalies. CMA and FISH are highly effective methods for the diagnosis of uniparental disomy and low-level mosaicism involving chromosome 9.

  • Clinical and genetic characteristics of patients with MN1 gene dysfunction after the two clinical case reports

    by Zh.G. Markova, A.S. Kuchina, L.A. Bessonova, V.V. Zabnenkova, S.V. Voronin, N.V. Shilova

    MN1 gene is localized in the q12.1 region of the Chromosome 22, consists of two exons and encodes a protein of 1320 amino acids. In 2020 it was for the first time shown that dysfunction of the MN1 gene causes a specific disease, CEBALID syndrome, which is characterized by malformations of the central nervous system and craniofacial skeleton. There are also isolated reports that overlapping microdeletions of 22q12.1, including the entire sequence of the MN1 gene, are associated with various clinical phenotypes, including developmental anomalies of the nervous system, facial dysmorphia and congenital heart defects. Authors represent the two new clinical case reports of dysfunction of the MN1 gene caused by a heterozygous deletion of 22q12.1 and a pathogenic variant of the nucleotide sequence in exon 2 of the MN1 gene, which were diagnosed in two patients with different phenotype anomalies. Conclusion: the variability of clinical features among the two presented cases was caused by different types of genetic variants. Deletion of the chromosomal region 22q12.1 leads to less pronounced clinical symptoms and difficulties in diagnosis.

  • Open Access

    Expanding the spectrum of clinical and genetic characteristics of distal arthrogryposis type 5 caused by heterozygous variants in the PIEZO2 gene

    by E. L. Dadali, T. V. Markova, Е. А. Мельник, S. S. Nikitin, I. V. Sharkova, O. V. Khalanskaya, Л. А. Бессонова, E. A. Shestopalova, O. P. Ryzhkova, S. I. Trofimova, et al.

    Pathogenic heterozygous variants in the PIEZO2 gene cause distal arthrogryposis type 5 – a rare autosomal dominant disease, which is characterized by the development of congenital contractures, ophthalmoparesis, ptosis and restrictive respiratory disorders. We have presented clinical and genetic characteristics of seven Russian patients with distal arthrogryposis type 5 caused by previously described and newly identified nucleotide variants in the PIEZO2 gene. It was shown that the most severe clinical manifestations were found in patients with newly identified nucleotide variants c.8238GA (p.Trp274Ter) and c.7095GT (p.Trp2365Cys), while in patients with other previously described variants c.8181_8183delAGA (p.Glu2727del) and c.2134AG (p.Met712Val) the clinical phenotype is more moderately expressed. The dynamics of phenotype formation were also noted. It has been shown that the disease progression may occur as the child grows and requires monitoring of this group of patients.

  • Open Access

    Special clinical manifestations and genetic characteristics of schaaf–Yang syndrome in Russian patients

    by E. L. Dadali, T. V. Markova, F. M. Bostanova, A. S. Kuchina, L. A. Bessonova, Е. А. Мельник, V. V. Zabnenkova, O. P. Ryzhkova, O. E. Agranovich

    A description of the clinical and genetic characteristics of four Russian patients with Schaaf–Yang syndrome, caused by previously described and newly identified nucleotide variants in MAGEL2 gene, is presented. It was shown that the most severe clinical manifestations were found in a patient with the new identified variant c.1828CT (p.Gln610Ter), while in a patient with a new nucleotide variant c.1609CT (p.Gln537Ter) the manifestations of the disease were moderate. Considering the significant similarity of the clinical manifestations of Schaaf–Yang syndrome with Prader–Willi syndrome, the criteria for their differential diagnosis are outlined, the use of which will help optimize the process of molecular genetic analysis aimed at finding the etiologic factor.


  • Open Access

    Four Novel Disease-Causing Variants in the NOTCH3 Gene in Russian Patients with CADASIL

    by Fatima Bostanova, Polina Tsygankova, Ilya Nagornov, Elena Dadali, Lyudmila Bessonova, Aleksey Kulesh, Viktor Drobakha, Irina Danchenko, Ilya Kanivets, Ekaterina Zakharova

    Background: Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is an inherited disease with unknown mechanisms and a broad phenotypic spectrum. It is caused by pathogenic variants in the NOTCH3 gene. The symptoms of the disease mainly include recurrent strokes with vascular risk factors, migraine with aura, dementia, and mood disturbances. Case presentation: Peripheral blood samples were collected from five patients from four unrelated families to extract genomic DNA. In four patients, analysis of exons 2, 3, 4, 5, 6 and adjacent intronic regions of the NOTCH3 gene was made via Sanger sequencing. Two previously undescribed nucleotide variants were identified in two patients: missense variant c.208G>T, (p.Gly70Cys) in exon 1 and splice-site variant c.341-1G>C in intron 3. Further DNA of two other patients were analyzed using a next-generation sequencing-based custom AmpliSeq™ panel for 59 genes associated with leukodystrophies. Two novel missense variants in the NOTCH3 gene were identified, c.1136G>A, (p.Cys379Tyr) in exon 7 and c.1547G>A, (p.Cys516Tyr) in exon 10. The pathogenic variant c.1547G>A, (p.Cys516Tyr) was confirmed in the fifth patient (family case) by Sanger sequencing. All patients had a history of headaches, transient ischemic attacks, memory impairment, and characteristics of MRI results. Three patients had strokes and two patients had psychiatric symptoms. Conclusion: We found four previously undescribed pathogenic variants in the NOTCH3 gene in five patients with CADASIL and described their clinical and genetic characteristics. These results expand the mutational spectrum of CADASIL.


  • Open Access

    Principles of the differential diagnosis of achondroplasia and pseudoachondroplasia

    by Tatiana V. Markova, Vladimir M. Kenis, Evgenii V. Melchenko, Dmitry A. Reshchikov, Aynur E. Alieva, Darya V. Osipova, Liudmila A. Bessonova, Tatiana S. Nagornova, Natalya N. Vasserman, Natalya Yu. Ogorodova, et al.

    BACKGROUND: Achondroplasia and pseudoachondroplasia are hereditary systemic skeletal dysplasias characterized by a certain similarity of clinical manifestations; however, they have different etiopathogenetic mechanisms and confirmation methods for molecular genetic diagnosis. Their common phenotypic features often make differential diagnosis difficult during the clinical examination of patients, planning DNA diagnostics, and appropriate time detection of neurosurgical and orthopedic complications. AIM: This study aimed to identify differential diagnostic criteria for achondroplasia and pseudoachondroplasia and optimize the strategy for their molecular genetic diagnosis. MATERIALS AND METHODS: A comprehensive examination of 76 children from 74 unrelated families aged 1 month to 18 years with phenotypic signs of achondroplasia and pseudoachondroplasia was conducted. To clarify the diagnosis through genealogical and amnestic analysis, clinical and neurological examination data according to the standard method and radiographic data were used. Molecular genetic confirmation of diseases was conducted by searching for hotspot mutations in the FGFR3 gene, assessing the number of GAC repeats located in exon 13 of the COMP gene, and new-generation sequencing of the target panel consisting of 166 genes responsible for hereditary skeletal pathology. RESULTS: Based on a comparative analysis of the specific phenotypic characteristics, the criteria for the differential diagnosis of achondroplasia and pseudoachondroplasia were identified. The leading signs of achondroplasia are disproportionate nanism from birth, macrocrania, and facial dysmorphism, which are not specific to pseudoachondroplasia. Certain radiological features are essential in the differential diagnosis of pseudoachondroplasia, which should be considered when referring to patients for molecular genetic analysis. A deletion of the GAC repeat c.1417_1419del in the COMP gene was identified in 27% of patients with pseudoachondroplasia. Thus, the analyses of these two mutations in FGFR3 and COMP were conducted first. In the absence of target mutations, further diagnostic search should be continued with a target panel consisting of 166 genes responsible for hereditary skeletal pathology or whole-exome sequencing. CONCLUSIONS: The analysis of the clinical, radiological, and molecular genetic characteristics of patients with achondroplasia and pseudoachondroplasia, together with the literature data analysis, made it possible to clarify the differential diagnostic criteria for these diseases and optimize the algorithm for their molecular genetic diagnosis.


  • Open Access

    Spectrum of Genes for Non-GJB2-Related Non-Syndromic Hearing Loss in the Russian Population Revealed by a Targeted Deafness Gene Panel

    by Olga Shatokhina, Nailya Galeeva, Anna Stepanova, Tatiana Markova, Maria Lalayants, Natalia Alekseeva, George Tavarkiladze, Tatiana Markova, Liudmila Bessonova, Marina Petukhova, et al.

    Hearing loss is one of the most genetically heterogeneous disorders known. Over 120 genes are reportedly associated with non-syndromic hearing loss (NSHL). To date, in Russia, there have been relatively few studies that apply massive parallel sequencing (MPS) methods to elucidate the genetic factors underlying non-GJB2-related hearing loss cases. The current study is intended to provide an understanding of the mutation spectrum in non-GJB2-related hearing loss in a cohort of Russian sensorineural NSHL patients and establish the best diagnostic algorithm. Genetic testing using an MPS panel, which included 33 NSHL and syndromic hearing loss (SHL) genes that might be misdiagnosed as NSHL genes, was completed on 226 sequentially accrued and unrelated patients. As a result, the molecular basis of deafness was found in 21% of the non-GJB2 NSHL cases. The total contribution pathogenic, and likely pathogenic, variants in the genes studied among all hereditary NSHL Russian patients was 12%. STRC pathogenic and likely pathogenic, variants accounted for 30% of diagnoses in GJB2-negative patients, providing the most common diagnosis. The majority of causative mutations in STRC involved large copy number variants (CNVs) (80%). Among the point mutations, the most common were c.11864G>A (p.Trp3955*) in the USH2A gene, c.2171_2174delTTTG (p.Val724Glyfs*6) in the STRC gene, and c.107A>C (p.His36Pro) and c.1001G>T (p.Gly334Val) in the SLC26A4 gene. Pathogenic variants in genes involved in SHL accounted for almost half of the cases with an established molecular genetic diagnosis, which were 10% of the total cohort of patients with non-GJB2-related hearing loss.